Bangladesh
· Delayed Price · Currency is BDT Silva Pharmaceuticals Statistics
Total Valuation
Silva Pharmaceuticals has a market cap or net worth of BDT 1.90 billion. The enterprise value is 1.77 billion.
| Market Cap | 1.90B |
| Enterprise Value | 1.77B |
Important Dates
The next estimated earnings date is Thursday, October 24, 2024.
| Earnings Date | Oct 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Silva Pharmaceuticals has 136.50 million shares outstanding.
| Shares Outstanding | 136.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 30.52% |
| Owned by Institutions (%) | n/a |
| Float | 66.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.10 |
| PB Ratio | 0.82 |
| P/FCF Ratio | 162.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 49.48, with an EV/FCF ratio of 150.95.
| EV / Earnings | -57.12 |
| EV / Sales | 2.89 |
| EV / EBITDA | 49.48 |
| EV / EBIT | n/a |
| EV / FCF | 150.95 |
Financial Position
The company has a current ratio of 13.23, with a Debt / Equity ratio of 2.03.
| Current Ratio | 13.23 |
| Quick Ratio | 5.69 |
| Debt / Equity | 2.03 |
| Debt / EBITDA | 1.31 |
| Debt / FCF | 4.00 |
| Interest Coverage | -6.56 |
Financial Efficiency
Return on equity (ROE) is -1.33% and return on invested capital (ROIC) is -0.65%.
| Return on Equity (ROE) | -1.33% |
| Return on Assets (ROA) | -0.62% |
| Return on Capital (ROIC) | -0.65% |
| Revenue Per Employee | 799,498 |
| Profits Per Employee | -40,409 |
| Employee Count | 587 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0.92 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.65% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -35.65% |
| 50-Day Moving Average | 15.02 |
| 200-Day Moving Average | 17.46 |
| Relative Strength Index (RSI) | 39.76 |
| Average Volume (20 Days) | 112,754 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Silva Pharmaceuticals had revenue of BDT 611.62 million and -30.91 million in losses. Loss per share was -0.23.
| Revenue | 611.62M |
| Gross Profit | 173.70M |
| Operating Income | -24.95M |
| Pretax Income | -23.50M |
| Net Income | -30.91M |
| EBITDA | 32.26M |
| EBIT | -24.95M |
| Loss Per Share | -0.23 |
Balance Sheet
The company has 178.53 million in cash and 46.83 million in debt, giving a net cash position of 131.70 million or 0.96 per share.
| Cash & Cash Equivalents | 178.53M |
| Total Debt | 46.83M |
| Net Cash | 131.70M |
| Net Cash Per Share | 0.96 |
| Equity (Book Value) | 2.31B |
| Book Value Per Share | 16.92 |
| Working Capital | 926.86M |
Cash Flow
In the last 12 months, operating cash flow was -16.66 million and capital expenditures 28.36 million, giving a free cash flow of 11.70 million.
| Operating Cash Flow | -16.66M |
| Capital Expenditures | 28.36M |
| Free Cash Flow | 11.70M |
| FCF Per Share | 0.09 |
Margins
Gross margin is 28.40%, with operating and profit margins of -4.08% and -5.05%.
| Gross Margin | 28.40% |
| Operating Margin | -4.08% |
| Pretax Margin | -3.84% |
| Profit Margin | -5.05% |
| EBITDA Margin | 5.27% |
| EBIT Margin | -4.08% |
| FCF Margin | 1.91% |
Dividends & Yields
This stock pays an annual dividend of 0.10, which amounts to a dividend yield of 0.72%.
| Dividend Per Share | 0.10 |
| Dividend Yield | 0.72% |
| Dividend Growth (YoY) | -66.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 0.72% |
| Earnings Yield | -1.63% |
| FCF Yield | 0.62% |
Stock Splits
The last stock split was on November 7, 2019. It was a forward split with a ratio of 1.05.
| Last Split Date | Nov 7, 2019 |
| Split Type | Forward |
| Split Ratio | 1.05 |